Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Telitacicept in the Treatment of Proliferative Glomerulonephritis With Monoclonal Immunoglobulin Deposits (PGNMID): A Prospective, Single-Arm Study

NCT07111338 is registered in ClinicalTrials.gov with Peking University First Hospital as lead sponsor.

NCT NCT07111338
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT07111338 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Telitacicept in the Treatment of Proliferative Glomerulonephritis With Monoclonal Immunoglobulin Deposits (PGNMID): A Prospective, Single-Arm Study
Lead sponsor
Peking University First Hospital
Phase
Phase 2
Overall status
Active, not recruiting
Start date
July 12, 2025
Completion date
May 29, 2027
Enrollment
10 (estimated)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

proliferative glomerulonephritis with monoclonal immunoglobulin deposits